Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value

The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of... RESEARCH ARTICLE The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value Uiju Cho, MD,* Hee Eun Kim, BS,* Woo Jin Oh, MD,* Min-Kyung Yeo, MD,*w Byung Joo Song, MD, PhD,z and Ahwon Lee, MD, PhD* reast cancer (BC) has heterogenous clinical outcomes Abstract: Markers of proliferation are considered to have prog- Band is composed of different genomic subtypes. Bio- nostic importance in breast cancer (BC). The Ki-67 index has been logical markers in BC have profound importance in de- reported as a prognostic factor, but standardized cutoff values and termining the type of adjuvant therapy, prediction and counting methods are not yet established. We assayed the Ki-67 monitoring of treatment response, and prognostic pa- labeling index (LI) of 589 consecutive operable BC patients who rameters. The proliferative status of the tumor is one of underwent surgical resection. Ki-67 immunostaining was per- the major prognostic factors in BC. A classic measure- formed, and the LI was manually counted using an image pro- ment of tumor cell proliferation is the mitotic activity cessing program. We also compared the manual cell count (MCC) index, which is a main part of the Nottingham histologic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value

Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Mar 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/the-long-term-prognostic-performance-of-ki-67-in-primary-operable-KCjCUXudju
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000164
pmid
25789536
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value Uiju Cho, MD,* Hee Eun Kim, BS,* Woo Jin Oh, MD,* Min-Kyung Yeo, MD,*w Byung Joo Song, MD, PhD,z and Ahwon Lee, MD, PhD* reast cancer (BC) has heterogenous clinical outcomes Abstract: Markers of proliferation are considered to have prog- Band is composed of different genomic subtypes. Bio- nostic importance in breast cancer (BC). The Ki-67 index has been logical markers in BC have profound importance in de- reported as a prognostic factor, but standardized cutoff values and termining the type of adjuvant therapy, prediction and counting methods are not yet established. We assayed the Ki-67 monitoring of treatment response, and prognostic pa- labeling index (LI) of 589 consecutive operable BC patients who rameters. The proliferative status of the tumor is one of underwent surgical resection. Ki-67 immunostaining was per- the major prognostic factors in BC. A classic measure- formed, and the LI was manually counted using an image pro- ment of tumor cell proliferation is the mitotic activity cessing program. We also compared the manual cell count (MCC) index, which is a main part of the Nottingham histologic

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2015

There are no references for this article.